Armis Biopharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Armis Biopharma, Inc. - overview
Established
2011
Location
Fort Collins, CO, US
Primary Industry
Biotechnology
About
Founded in 2011 and based in Colorado, the US, Armis Biopharma, Inc. aka CHD Bioscience, Inc. is a biopharmaceutical firm that specializes in developing antimicrobial medicines to combat drug-resistant illnesses. In February 2022, CHD Bioscience, Inc.
raised USD 5. 7 million in venture debt funding from unspecified investors. As of 2022, Theodore E. Ziemann is the CEO of the company.
The Company provides technology, Veriox®, which is a proprietary peracid/hydrogen peroxide-based non-systemic, non-resistant antimicrobial agent. Veriox® offers a unique mechanism of action that reduces the danger of Gram+, Gram-, viral, and fungal disease resistance while also neutralizing chemical and biological warfare agents. The firm's products include ArmiClenz, ArmiVET, ArmiCare, and VeriFixx. The organization's products also aid in the treatment of skin infections and the healing of wounds.
Current Investors
The National Institutes of Health
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Dermatology
Website
www.armisbiopharma.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.